+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Age Related Macular Degeneration - Pipeline Review, H2 2019

  • ID: 4901397
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 753 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 3SBio Inc
  • Astellas Pharma Inc
  • CureLab Oncology Inc
  • Hemera Biosciences Inc
  • Mitotech SA
  • Phision Therapeutics
  • MORE
Age Related Macular Degeneration - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Age Related Macular Degeneration - Pipeline Review, H2 2019, provides an overview of the Age Related Macular Degeneration (Ophthalmology) pipeline landscape.

Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in depreciation of the macula that may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity etc. Symptoms include development of blind spot and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy and medication such as anti-angiogenic drugs.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Age Related Macular Degeneration - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Age Related Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 15, 32, 32, 3, 154, 31 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 16 and 1 molecules, respectively.

Age Related Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Age Related Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Age Related Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Age Related Macular Degeneration (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Age Related Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 3SBio Inc
  • Astellas Pharma Inc
  • CureLab Oncology Inc
  • Hemera Biosciences Inc
  • Mitotech SA
  • Phision Therapeutics
  • MORE
Introduction
Age Related Macular Degeneration - Overview
Age Related Macular Degeneration - Therapeutics Development
Age Related Macular Degeneration - Therapeutics Assessment
Age Related Macular Degeneration - Companies Involved in Therapeutics Development
Age Related Macular Degeneration - Drug Profiles
Age Related Macular Degeneration - Dormant Projects
Age Related Macular Degeneration - Discontinued Products
Age Related Macular Degeneration - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Age Related Macular Degeneration, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Products under Development by Companies, H2 2019 (Contd..11), H2 2019
Products under Development by Companies, H2 2019 (Contd..12), H2 2019
Products under Development by Companies, H2 2019 (Contd..13), H2 2019
Products under Development by Companies, H2 2019 (Contd..14), H2 2019
Products under Development by Companies, H2 2019 (Contd..15), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Age Related Macular Degeneration - Pipeline by 3SBio Inc, H2 2019
Age Related Macular Degeneration - Pipeline by 4D Molecular Therapeutics Inc, H2 2019
Age Related Macular Degeneration - Pipeline by Abpro Corp, H2 2019
Age Related Macular Degeneration - Pipeline by Abzyme Therapeutics LLC, H2 2019
Age Related Macular Degeneration - Pipeline by Achillion Pharmaceuticals Inc, H2 2019
Age Related Macular Degeneration - Pipeline by Acucela Inc, H2 2019
Age Related Macular Degeneration - Pipeline by AdAlta Ltd, H2 2019
Age Related Macular Degeneration - Pipeline by Adverum Biotechnologies Inc, H2 2019
Age Related Macular Degeneration - Pipeline by Aerie Pharmaceuticals Inc, H2 2019

List of Figures
Number of Products under Development for Age Related Macular Degeneration, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 3SBio Inc
  • 4D Molecular Therapeutics Inc
  • Abpro Corp
  • Abzyme Therapeutics LLC
  • Achillion Pharmaceuticals Inc
  • Acucela Inc
  • AdAlta Ltd
  • Adverum Biotechnologies Inc
  • Aerie Pharmaceuticals Inc
  • Aerpio Pharmaceuticals Inc
  • Aevitas Therapeutics Inc
  • Affilogic SAS
  • Aibios Co Ltd
  • Aldeyra Therapeutics Inc
  • Alimera Sciences Inc
  • Alkahest Inc
  • Alkeus Pharmaceuticals Inc
  • Allegro Ophthalmics LLC
  • Allergan Plc
  • Allgenesis Biotherapeutics Inc
  • Alpine Biotherapeutics Corp
  • Alteogen Inc
  • Alzheon Inc
  • Amarantus Bioscience Holdings Inc
  • Amarna Therapeutics BV
  • Amyndas Pharmaceuticals LLC
  • AngioGenex Inc
  • Anida Pharma Inc
  • Annexon Inc
  • Apellis Pharmaceuticals Inc
  • Apexian Pharmaceuticals Inc
  • Apexigen Inc
  • Applied Genetic Technologies Corp
  • AptaBio Therapeutics Inc
  • Aptamer Sciences Inc
  • Ascentage Pharma Group International
  • Asclepiumm Taiwan Co Ltd
  • AsclepiX Therapeutics Inc
  • Astellas Pharma Inc
  • AVEO Oncology Inc
  • Avixgen Inc
  • Beijing Eastern Biotech Co Ltd
  • BellBrook Labs LLC
  • Benitec Biopharma Ltd
  • Beta Therapeutics Pty Ltd
  • Bio-Thera Solutions Ltd
  • BIOCND Inc
  • Biocure Technology Inc
  • Bioeq GmbH
  • Biogen Inc
  • Biokine Therapeutics Ltd
  • Biomics Biotechnologies Co Ltd
  • Biophytis SA
  • Boehringer Ingelheim International GmbH
  • Bridge Biotherapeutics Inc
  • Cadila Healthcare Ltd
  • Catalyst Biosciences Inc
  • Cell Care Therapeutics Inc
  • Cell Cure Neurosciences Ltd
  • Cell Medica Ltd
  • Celon Pharma SA
  • Charlesson LLC
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd
  • Chong Kun Dang Pharmaceutical Corp
  • CHS Pharma Inc
  • Cinnagen Co
  • Cipla BioTec Pvt Ltd
  • CJ HealthCare Corp
  • Clayton Biotechnologies Inc
  • Clearside BioMedical Inc
  • Clover Biopharmaceuticals
  • Coherus BioSciences Inc
  • CureLab Oncology Inc
  • Daiichi Sankyo Co Ltd
  • DNX Biopharmaceuticals Inc
  • Dobecure SL
  • Dong-A Socio Holdings Co Ltd
  • EirGenix Inc
  • Elasmogen Ltd
  • Elsalys Biotech SA
  • Envisia Therapeutics Inc
  • Enzene Biosciences Ltd
  • Epygen Biotech Pvt Ltd
  • Everglades Biopharma LLC
  • Exonate Ltd
  • Eye Co Pty Ltd
  • Eyedesis Biosciences LLC
  • EyeGate Pharmaceuticals Inc
  • EyePoint Pharmaceuticals Inc
  • Eyestem Research Pvt Ltd
  • Eyevensys SAS
  • F. Hoffmann-La Roche Ltd
  • Feramda Ltd
  • FirstString Research Inc
  • Formycon AG
  • Galimedix Therapeutics Ltd
  • Gemini Therapeutics Inc
  • Gene Signal International SA
  • Gene Techno Science Co Ltd
  • Genentech Inc
  • Generium
  • GenSight Biologics SA
  • Graybug Vision Inc
  • Gyroscope Therapeutics Ltd
  • Hanlim Pharm Co Ltd
  • Hemera Biosciences Inc
  • Hengenix Biotech Inc
  • Huabo Biopharm Co Ltd
  • Huons Global Co Ltd
  • Ichor Therapeutics Inc
  • Iconic Therapeutics Inc
  • Ildong Pharmaceutical Co Ltd
  • Immupharma Plc
  • Inflammasome Therapeutics Inc
  • Innovent Biologics Inc
  • Ionis Pharmaceuticals Inc
  • Isarna Therapeutics GmbH
  • iTherapeutics Corp
  • iVeena LLC
  • IVERIC bio Inc
  • Jeil Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Kala Pharmaceuticals Inc
  • Kalos Therapeutics Inc
  • Katairo GmbH
  • Kodiak Sciences Inc
  • Kyowa Kirin Co Ltd
  • Lead Discovery Center GmbH
  • Lin Bioscience Inc
  • Lupin Ltd
  • Luye Pharma Group Ltd
  • Mabion SA
  • MacuCLEAR Inc
  • MeiraGTx Holdings Plc
  • Mitotech SA
  • Mitsubishi Tanabe Pharma Corp
  • Mor Research Applications Ltd
  • Mperia Therapeutics Inc
  • NanoScope Technologies LLC
  • Nanoscope Therapeutics Inc
  • Neovacs SA
  • NeuBase Therapeutics Inc
  • NeuExcell Therapeutics Inc
  • NGM Biopharmaceuticals Inc
  • Novartis AG
  • NovelMed Therapeutics Inc
  • Novelty Nobility Inc
  • OccuRx Pty Ltd
  • Ocugen Inc
  • Ocular Therapeutix Inc
  • OcuNexus Therapeutics Inc
  • ODIN Biotech Partners LLC
  • OliX Pharmaceuticals Inc
  • Omeros Corp
  • ONL Therapeutics Inc
  • Opthea Ltd
  • Outlook Therapeutics Inc
  • Oxford BioMedica Plc
  • Oxstem Ltd
  • Oxurion NV
  • PanOptica Inc
  • Paras Biopharmaceuticals Finland Oy
  • Pfizer Inc
  • Phanes Therapeutics Inc
  • PharmAbcine Inc
  • Phio Pharmaceuticals Corp
  • Phision Therapeutics
  • PlantForm Corp
  • Pleryon Therapeutics Ltd
  • Polus Inc
  • Profarma
  • Promedior Inc
  • Qilu Pharmaceutical Co Ltd
  • Reflexion Pharmaceuticals Inc
  • Regen BioPharma Inc
  • Regeneron Pharmaceuticals Inc
  • RegenxBio Inc
  • Reliance Life Sciences Pvt Ltd
  • RemeGen Ltd
  • Retrotope Inc
  • RheinCell Therapeutics GmbH
  • Ribomic Inc
  • RiniSight Inc
  • Samsung Bioepis Co Ltd
  • SanBio Inc
  • SciFluor Life Sciences LLC
  • Semathera Inc
  • Senju Pharmaceutical Co Ltd
  • Shanghai Junshi Bioscience Co Ltd
  • Splash Pharmaceuticals Inc
  • Stealth BioTherapeutics Corp
  • Sumitomo Dainippon Pharma Co Ltd
  • Sustained Nano Systems LLC
  • Suzhou Kintor Pharmaceutical Inc
  • Suzhou Stainwei Biotech Inc
  • Sylentis SAU
  • Taejoon Pharm Co Ltd
  • Tarsius Pharma Ltd
  • TechnoPhage SA
  • TOT Biopharm Co Ltd
  • TRACON Pharmaceuticals Inc
  • Translatum Medicus Inc
  • TreeFrog Therapeutics SAS
  • Visgenx Inc
  • Wellstat Ophthalmics Corp
  • Xbrane Biopharma AB
  • Xcovery Holding Company LLC
  • YD Life Science Co
  • Zhejiang Doer Biologics Corp
Note: Product cover images may vary from those shown
Adroll
adroll